Navigation Links
AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results
Date:8/12/2008

All amounts are in U.S. dollars

QUEBEC CITY, Aug. 12 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), a global biopharmaceutical company focused on endocrinology and oncology, today reported financial and operating results for the second quarter ended June 30, 2008.

Second Quarter 2008 Highlights

- Advancement of cetrorelix Phase 3 program in BPH;

- First efficacy trial: patient enrollment completed;

- Second efficacy trial: patient enrollment ongoing / completion

planned for third quarter of 2008 remains on target;

- Safety trial: first patient dosing initiated.

- Completion of sale of Quebec City building for $7.1 million.

Juergen Ernst, Chairman, Interim President and CEO at AEterna Zentaris commented, "During the quarter, we achieved our key objectives as our Phase 3 program in BPH with our lead compound cetrorelix met all recruitment goals and remains on track, with first results expected in the third quarter of 2009. Furthermore, we monetized our Quebec City building which provided additional non-dilutive funding. Over the next few months, we will focus on advancing our Phase 3 program in BPH with cetrorelix, while we endeavour to conclude additional non-dilutive transactions and strategic partnerships."

CONSOLIDATED RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2008

Consolidated sales and royalties increased to $8.2 million for the three-month period ended June 30, 2008, compared to $7.7 million for the same period in 2007. The increase in sales and royalties for the three-month period ended June 30, 2008 is related primarily to additional sales of Cetrotide(R), partly offset by the exclusion of sales from Impavi
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
2. AEterna Zentaris to Announce Second Quarter 2008 Financial and Operating Results on August 12, 2008
3. AEterna Zentaris Sells Quebec City Building for $7.1 million
4. AEterna Zentaris to Present at Upcoming Rodman & Renshaw Global Healthcare Conference and AUA Annual Meeting
5. AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal
6. AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results
7. AEterna Zentaris to Announce First Quarter 2008 Financial and Operating Results and Hold Annual Shareholder Meeting on May 7, 2008
8. AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan
9. AEterna Zentaris Partner, Spectrum, Provides Update on Ozarelix in Benign Prostatic Hyperplasia
10. AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia
11. AEterna Zentaris Announces Changes to its Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... to settle into equilibriuma state of unchanging balance ... of non-equilibrium conditions where new possibilities lie. Non-equilibrium ... such as temperature fluctuations, freezing and melting, or ... body temperature, airplanes to fly, and the Earth ... even though these conditions exist naturally and are ...
(Date:7/24/2014)... Research and Markets has announced ... Analytical Instruments Market 2014-2018" report to their offering. ... Genomics is the study of the gene and its ... and functions of proteomes or sets of proteins by ... involves the mapping of genes and DNA sequencing to ...
(Date:7/24/2014)... 2014 SRI International has been awarded a ... of Allergy and Infectious Diseases (NIAID), part of the ... potential therapies for HIV infection and AIDS. The contract ... AIDS and the complications and opportunistic infections associated with ... transmission of HIV. According to the ...
(Date:7/24/2014)... 2014 Three companies from the angelMD ... Big C Competition. Out of 700 competition entrants, Chiron ... the semi-final round. In this round twenty teams are ... complete with mentoring from thought-leaders and medical entrepreneurs from ... the angelMD commitment to the Livestrong vision around the ...
Breaking Biology Technology:New approach to form non-equilibrium structures 2Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 33 angelMD Startups Make Livestrong Big C Semi-finals 2
... - Ranked Number 7 out of top 20 Employers ... 9 EMD Serono, Inc., an affiliate,of Merck KGaA, ... Science magazine as a top employer in the biotechnology ... 20 employers,across the life sciences., "We are honored ...
... (Nasdaq: ERES ), a leading provider of ... to the pharmaceutical,biotechnology, medical device, and related industries, ... quarter results for the period ended,September 30, 2008 ... closes.,After the release, the Company will host a ...
... Million RMB Commercial Bank Loan With Interest Payment ... Biotech Ltd. (Amex:,SVA), a vaccine-focused biotech company in ... Promotion Association at the,Zhongguancun Science and Technology Park ... of that program, Sinovac Biotech Co. Ltd.,s,("the Company") ...
Cached Biology Technology:EMD Serono Named as a Top Employer by Science Magazine 2eResearchTechnology, Inc. to Announce 2008 Third Quarter Results on October 30, 2008 2Sinovac's Credit Rating Upgraded to AAZ, Second Highest Rating 2Sinovac's Credit Rating Upgraded to AAZ, Second Highest Rating 3
(Date:7/24/2014)... -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the ... Phase 3 study of Zerenex (ferric citrate), the Company,s ... of hyperphosphatemia in patients with end-stage renal disease (ESRD) ... delivery with FErric CiTrate in EsrD) was published online ... of Nephrology ( JASN ). , ...
(Date:7/24/2014)... has different effects on different species of fish, ... of Bristol and Exeter which tested fish anti-predator ... a flying seagull predator model when exposed to ... European minnows. , Lead author Dr Irene ... "Noise levels in many aquatic environments have increased ...
(Date:7/24/2014)... own microbial terroir, meaning the microbial populations found on ... product, creating the final flavor according to research published ... Environmental Microbiology . This is the first time investigators ... , Many sake makers inoculate with both bacteria ... the University of California, Davis, but he and his ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4The microbes make the sake brewery 2
... is pleased to announce the winners of its 2009 ... Plenary Session of the ESA Annual Meeting in Indianapolis, ... be presented on Tuesday, December 15, 7:00-8:00 p.m. ... with full biographies and photos available at http://www.entsoc.org/resources/press_releases/2009-awards.htm ...
... recently completed a comparative analysis of marine ecosystems in ... factors support fisheries production, leading to new insights that ... Known as MENU, for Marine Ecosystems of Norway and ... NOAA Fisheries Service,s Northeast Fisheries Science Center and Alaska ...
... The University of North Carolina at Chapel Hill is ... part of an unprecedented large-scale, collaborative effort by the National ... (NHGRI) to systematically characterize the genomic changes that occur in ... a five-year award, expected to bring $13 to $20 million ...
Cached Biology News:Entomological Society of America names 2009 award winners 2Joint US-Norwegian study provides new insights into marine ecosystems and fisheries production 2Joint US-Norwegian study provides new insights into marine ecosystems and fisheries production 3UNC awarded Cancer Genome Atlas grant 2
... ExonHit can design custom microarrays to detect ... list. Proprietary algorithms are used to ... from high quality, spliced cDNAs aligned to ... in a custom SpliceArray is profiled with ...
... signaling of the members of the GPCR ... alternative splicing--which has important implications for drug ... a classical expression profiling and at the ... forms of the gene that are expressed ...
Mouse monoclonal antibody raised against a partial recombinant ST3GAL2. NCBI Entrez Gene ID = ST3GAL2...
... manufactured for DNA purification from agarose gels ... light. The Purification of DNA from an ... work. The conventional method of visualizing DNA ... light damages DNA and significantly decreases cloning ...
Biology Products: